The new guidance aims to address the under-treatment of heart failure by providing step-by-step recommendations for prescribing ACE inhibitors and beta-blockers. It is expected to encourage more doctors to adequately treat patients, improving survival and quality of life.
Ketek has been granted marketing authorisation by the European Commission for treating community-acquired respiratory tract infections, including those caused by resistant bacteria. The approval follows positive opinion from the Committee for Proprietary Medicinal Products and will be available in all 15 EU-Member States.
Exanta, a novel oral anticoagulant, has demonstrated comparable efficacy to warfarin or low molecular weight heparin in preventing blood clots. The European phase III trial showed that Exanta is effective and well-tolerated for VTE prophylaxis in orthopaedic surgery.
A new report reveals that bipolar disorder costs the UK over £2 billion annually, with up to 85% associated with lost productivity. The study suggests Risperdal as an effective treatment for acute bipolar mania, improving symptoms by at least 50% in patients.
The study suggests KETEK is an effective option for treating community-acquired respiratory tract infections, which cause 50 million deaths globally each year. KETEK demonstrated high activity against a range of bacteria, including pneumococci and S. pyogenes, with up to 99.6% susceptibility
UCB-Bioproducts is providing commercial quantities of bivalirudin for Angiomax, a thrombin-specific anticoagulant. The company's unique process technology enables the production of synthetic peptide-based APIs, and its regulatory support ensures compliance with FDA regulations.
Researchers found that combining a long-acting AT1-receptor blocker with an ACE inhibitor reduces blood pressure and albumin excretion in hypertensive type 2 diabetic patients. The study also showed that combined treatment is more effective than using either drug alone.
A growing global problem: Bacterial resistance to antibiotics is on the rise, with penicillin and macrolide antibiotics showing high levels of resistance. Telithromycin, a new ketolide antibiotic, has shown promise in combating treatment-resistant respiratory tract infections.
A Phase III study found significant improvements in overall survival, disease-free status, and complete remission rates for patients with aggressive non-Hodgkin's lymphoma treated with MabThera and CHOP chemotherapy. Survival at 1-year was 83% for the rituximab combination therapy group compared to 68% for those receiving CHOP alone.
The Val-HeFT study showed significant effects of an AT1-receptor blocker on mortality and morbidity in patients with heart failure when added to ACE inhibitor therapy. The CHARM study programme aims to provide more definitive data on the benefits of AT1-receptor blockers in treating heart failure.
The European Commission has designated Mylotarg as an orphan medicinal product for treating patients with CD33-positive relapsed acute myeloid leukemia. The compound represents a novel anticancer therapy and has shown promising results in clinical trials.
The DIRECT programme aims to establish whether candesartan cilexetil can prevent and treat diabetic retinopathy. The trial will investigate the effect of RAS blockade on diabetic patients with and without retinopathy.
Researchers found that up to 96% of Parkinson's patients experience serious sleep disturbances, often overlooked by doctors. A new study suggests that cabergoline, a long-acting dopamine agonist, offers significant benefits in improving symptoms of sleep disturbance and daytime sleepiness.
A new study published in JAMA found that initiating therapy with MIRAPEX delayed the onset of motor complications and reduced their incidence compared to patients on initial treatment with levodopa. At two years, 72% of MIRAPEX-treated patients were free from motor complications.
A clinical trial of Mylotarg found disease remission in 34% of patients under 60 and 26% of those over 60, with a median overall survival of 5.9 months. No significant differences were seen in adverse events between age groups.
Phase I clinical trials show CCI-779's potential as a cancer treatment, inhibiting tumor growth with minimal side effects. The drug targets the mTOR pathway, which may selectively arrest the development of certain cancer cells.
The virtual reality experience, Paved with Fear, simulates daily activities for psychiatrists to grasp the impact of auditory and visual hallucinations. Developed in collaboration with patients, this innovative technology provides a unique understanding of the condition, ultimately enhancing treatment effectiveness.
A new study found that an oral-solution form of Risperdal is just as effective as intramuscular injections in reducing symptoms of psychotic agitation. The oral solution may be a more acceptable alternative for both caregivers and patients, promoting patient choice and compliance.
A new study published at the CINP meeting found that treating patients with schizophrenia with Risperdal resulted in a daily savings of $2.80 US per patient, corresponding to an annual saving of $1,022 US. This cost-effectiveness analysis may translate into significant figures given the high prevalence of schizophrenia worldwide.
Dr. Paul Janssen received the CINP-Pfizer Pioneers in Psychopharmacology Award for his work revolutionizing treatment of psychosis and introducing risperidone, a first-choice antipsychotic worldwide.
Two new Phase III studies published in Neurology show that Reminyl (galantamine) significantly improves cognition, global function, and behavioral symptoms of Alzheimer's disease over a period of 12 months. The treatment also maintains activities of daily functioning for patients with mild to moderate Alzheimer's disease.
New research from the HOT Study reveals significant differences in the response to antihypertensive treatment between age and sex groups. Women with hypertension achieve target blood pressures more easily than men, while older patients exhibit improved blood pressure control and lower risk of adverse events.
The METHRO II study found that H 376/95 was effective in preventing venous thrombo-embolism in patients undergoing total hip or total knee replacement surgery. The incidence of venous thrombo-embolism was significantly lower with the highest dosage of H 376/95 compared to dalteparin.
A new study finds that Risperdal treatment reduces clinical outcomes, relapse risk by 30%, and significantly lowers medication costs compared to olanzapine. The results suggest that better schizophrenia treatment can improve patients' lives while reducing healthcare burdens.
A new study suggests Reminyl, a treatment for Alzheimer's disease, provides significant cognitive and functional improvements in patients. The medication has been shown to delay the emergence of behavioral symptoms and maintain daily functioning for up to a year.